{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:06:35Z","timestamp":1790247995633,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02922-y","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:28:01Z","timestamp":1790245681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breast cancer-associated fibroblast-derived exosomal miR-1290 promotes triple-negative breast cancer cell proliferation"],"prefix":"10.1038","volume":"11","author":[{"given":"Jinkwon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taesang","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-4735","authenticated-orcid":false,"given":"Gyeonghwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hwan","family":"Tae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-gi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Seung","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhyang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Rok","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hwa","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-8812","authenticated-orcid":false,"given":"Mi-Young","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9280-5898","authenticated-orcid":false,"given":"Tae-Su","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-9390","authenticated-orcid":false,"given":"Hyun-Soo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"2922_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Prim. 5, 66 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2922_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288\u2013300 (2019).","journal-title":"JAMA"},{"key":"2922_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2922_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.molcel.2015.10.031","volume":"60","author":"S Koren","year":"2015","unstructured":"Koren, S. & Bentires-Alj, M. Breast tumor heterogeneity: source of fitness, hurdle for therapy. Mol. Cell 60, 537\u2013546 (2015).","journal-title":"Mol. Cell"},{"key":"2922_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fmed.2017.00227","volume":"4","author":"G Turashvili","year":"2017","unstructured":"Turashvili, G. & Brogi, E. Tumor heterogeneity in breast cancer. Front. Med. 4, 227 (2017).","journal-title":"Front. Med."},{"key":"2922_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tcb.2019.03.003","volume":"29","author":"K Hinohara","year":"2019","unstructured":"Hinohara, K. & Polyak, K. Intratumoral heterogeneity: more than just mutations. Trends Cell Biol. 29, 569\u2013579 (2019).","journal-title":"Trends Cell Biol."},{"key":"2922_CR7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"2922_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"2922_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2922_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174\u2013186 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2922_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13046-017-0528-y","volume":"36","author":"P Zheng","year":"2017","unstructured":"Zheng, P. et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J. Exp. Clin. Cancer Res. 36, 53 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2922_CR12","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.cell.2012.11.024","volume":"151","author":"V Luga","year":"2012","unstructured":"Luga, V. et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151, 1542\u20131556 (2012).","journal-title":"Cell"},{"key":"2922_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.omtn.2019.11.024","volume":"19","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. MicroRNA-181d-5p-containing exosomes derived from CAFs promote EMT by regulating CDX2\/HOXA5 in breast cancer. Mol. Ther. Nucleic Acids 19, 654\u2013667 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2922_CR14","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.7150\/thno.53412","volume":"11","author":"B Chen","year":"2021","unstructured":"Chen, B. et al. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. Theranostics 11, 3932\u20133947 (2021).","journal-title":"Theranostics"},{"key":"2922_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu, T. & Dai, Y. Tumor microenvironment and therapeutic response. Cancer Lett. 387, 61\u201368 (2017).","journal-title":"Cancer Lett."},{"key":"2922_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.trecan.2020.02.020","volume":"6","author":"EC Madden","year":"2020","unstructured":"Madden, E. C., Gorman, A. M., Logue, S. E. & Samali, A. Tumour cell secretome in chemoresistance and tumour recurrence. Trends Cancer 6, 489\u2013505 (2020).","journal-title":"Trends Cancer"},{"key":"2922_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel, G., D\u2019Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213\u2013228 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2922_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281\u2013297 (2004).","journal-title":"Cell"},{"key":"2922_CR19","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng, Y. & Croce, C. M. The role of MicroRNAs in human cancer. Signal Transduct. Target Ther. 1, 15004 (2016).","journal-title":"Signal Transduct. Target Ther."},{"key":"2922_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01268-0","volume":"21","author":"X Bai","year":"2023","unstructured":"Bai, X. et al. Exo-miR-1290-induced by COX-2 overexpression promotes cancer-associated fibroblasts activation and tumor progression by CUL3-Nrf2 pathway in lung adenocarcinoma. Cell Commun. Signal 21, 242 (2023).","journal-title":"Cell Commun. Signal"},{"key":"2922_CR21","doi-asserted-by":"publisher","first-page":"215726","DOI":"10.1016\/j.canlet.2022.215726","volume":"540","author":"SR Sirkisoon","year":"2022","unstructured":"Sirkisoon, S. R. et al. Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2\u2192 CNTF axis to promote progression of brain metastases. Cancer Lett. 540, 215726 (2022).","journal-title":"Cancer Lett."},{"key":"2922_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01364-w","volume":"17","author":"B Jiang","year":"2024","unstructured":"Jiang, B., Xiao, S., Zhang, S. & Xiao, F. The miR-1290\/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion. J. Ovarian Res. 17, 52 (2024).","journal-title":"J. Ovarian Res."},{"key":"2922_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/cac2.12536","volume":"44","author":"J Lee","year":"2024","unstructured":"Lee, J. et al. Positive regulation of cell proliferation by the miR-1290-EHHADH axis in hepatocellular carcinoma. Cancer Commun. 44, 705\u2013709 (2024).","journal-title":"Cancer Commun."},{"key":"2922_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4161\/cbt.10.4.12426","volume":"10","author":"XH Jiang","year":"2010","unstructured":"Jiang, X. H. et al. Frequent hyperphosphorylation of AS160 in breast cancer. Cancer Biol. Ther. 10, 362\u2013367 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"2922_CR25","doi-asserted-by":"publisher","first-page":"14599","DOI":"10.1074\/jbc.C300063200","volume":"278","author":"H Sano","year":"2003","unstructured":"Sano, H. et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J. Biol. Chem. 278, 14599\u201314602 (2003).","journal-title":"J. Biol. Chem."},{"key":"2922_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cmet.2005.09.005","volume":"2","author":"L Eguez","year":"2005","unstructured":"Eguez, L. et al. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. Cell Metab. 2, 263\u2013272 (2005).","journal-title":"Cell Metab."},{"key":"2922_CR27","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.immuni.2021.06.007","volume":"54","author":"SS Gabriel","year":"2021","unstructured":"Gabriel, S. S. et al. Transforming growth factor-\u03b2-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection. Immunity 54, 1698\u20131714. e1695 (2021).","journal-title":"Immunity"},{"key":"2922_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","volume":"11","author":"A Garami","year":"2003","unstructured":"Garami, A. et al. Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457\u20131466 (2003).","journal-title":"Mol. Cell"},{"key":"2922_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"2922_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/ncb2763","volume":"15","author":"CC Dibble","year":"2013","unstructured":"Dibble, C. C. & Manning, B. D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 15, 555\u2013564 (2013).","journal-title":"Nat. Cell Biol."},{"key":"2922_CR31","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471\u2013484 (2006).","journal-title":"Cell"},{"key":"2922_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. Cell Metab. 19, 373\u2013379 (2014).","journal-title":"Cell Metab."},{"key":"2922_CR33","doi-asserted-by":"crossref","unstructured":"Tian, T., Li, X. & Zhang, J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int. J. Mol. Sci. 20 (2019).","DOI":"10.3390\/ijms20030755"},{"key":"2922_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274\u2013293 (2012).","journal-title":"Cell"},{"key":"2922_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/13696998.2016.1273228","volume":"20","author":"DB Rose","year":"2017","unstructured":"Rose, D. B., Nellesen, D., Neary, M. P. & Cai, B. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic. J. Med. Econ. 20, 395\u2013404 (2017).","journal-title":"J. Med. Econ."},{"key":"2922_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29425-y","volume":"13","author":"MJ Rodriguez","year":"2023","unstructured":"Rodriguez, M. J. et al. Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models. Sci. Rep. 13, 2710 (2023).","journal-title":"Sci. Rep."},{"key":"2922_CR37","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI41680","volume":"120","author":"TW Miller","year":"2010","unstructured":"Miller, T. W. et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor\u2013positive human breast cancer. J. Clin. Investig. 120, 2406\u20132413 (2010).","journal-title":"J. Clin. Investig."},{"key":"2922_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","volume":"1","author":"VS Rodrik-Outmezguine","year":"2011","unstructured":"Rodrik-Outmezguine, V. S. et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1, 248\u2013259 (2011).","journal-title":"Cancer Discov."},{"key":"2922_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.molcel.2017.06.033","volume":"67","author":"S-O Yoon","year":"2017","unstructured":"Yoon, S.-O. et al. Focal adhesion-and IGF1R-dependent survival and migratory pathways mediate tumor resistance to mTORC1\/2 inhibition. Mol. Cell 67, 512\u2013527 e514 (2017).","journal-title":"Mol. Cell"},{"key":"2922_CR40","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/s41388-023-02737-z","volume":"42","author":"D Meng","year":"2023","unstructured":"Meng, D. et al. A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer. Oncogene 42, 2207\u20132217 (2023).","journal-title":"Oncogene"},{"key":"2922_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63310-2","volume":"10","author":"A El Guerrab","year":"2020","unstructured":"El Guerrab, A., Bamdad, M., Bignon, Y.-J., Penault-Llorca, F. & Aubel, C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci. Rep. 10, 6367 (2020).","journal-title":"Sci. Rep."},{"key":"2922_CR42","doi-asserted-by":"publisher","first-page":"641449","DOI":"10.3389\/fcell.2021.641449","volume":"9","author":"A Ianza","year":"2021","unstructured":"Ianza, A., Sirico, M., Bernocchi, O. & Generali, D. Role of the IGF-1 axis in overcoming resistance in breast cancer. Front. Cell Dev. Biol. 9, 641449 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2922_CR43","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Investig. 118, 3065\u20133074 (2008).","journal-title":"J. Clin. Investig."},{"key":"2922_CR44","doi-asserted-by":"publisher","first-page":"e0131400","DOI":"10.1371\/journal.pone.0131400","volume":"10","author":"EY Leung","year":"2015","unstructured":"Leung, E. Y., Askarian-Amiri, M., Finlay, G. J., Rewcastle, G. W. & Baguley, B. C. Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1\/2 inhibitors in cultured breast cancer cell lines. PLoS One 10, e0131400 (2015).","journal-title":"PLoS One"},{"key":"2922_CR45","doi-asserted-by":"publisher","first-page":"735","DOI":"10.15252\/emmm.201404346","volume":"7","author":"C Duluc","year":"2015","unstructured":"Duluc, C. et al. Pharmacological targeting of the protein synthesis mTOR\/4E-BP 1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol. Med. 7, 735\u2013753 (2015).","journal-title":"EMBO Mol. Med."},{"key":"2922_CR46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu, F. et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct. Target Ther. 6, 218 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2922_CR47","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3390\/ijms19082453","volume":"19","author":"F Conciatori","year":"2018","unstructured":"Conciatori, F. et al. Role of mTOR signaling in tumor microenvironment: an overview. Int J. Mol. Sci. 19, 2453 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"2922_CR48","doi-asserted-by":"publisher","first-page":"774103","DOI":"10.3389\/fimmu.2021.774103","volume":"12","author":"S Mafi","year":"2022","unstructured":"Mafi, S. et al. mTOR-mediated regulation of immune responses in cancer and tumor microenvironment. Front. Immunol. 12, 774103 (2022).","journal-title":"Front. Immunol."},{"key":"2922_CR49","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ijc.31931","volume":"144","author":"YR Lee","year":"2019","unstructured":"Lee, Y. R. et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int. J. Cancer 144, 1444\u20131452 (2019).","journal-title":"Int. J. Cancer"},{"key":"2922_CR50","first-page":"291","volume":"23","author":"A Ruifrok","year":"2001","unstructured":"Ruifrok, A. Quantification of histochemical staining by color deconvolution. Anal. Quant. Cytol. Histol. 23, 291\u2013299 (2001).","journal-title":"Anal. Quant. Cytol. Histol."},{"key":"2922_CR51","first-page":"716","volume":"109","author":"K McCarty Jr","year":"1985","unstructured":"McCarty, K. Jr, Miller, L., Cox, E., Konrath, J. & McCarty Sr, K. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab Med. 109, 716\u2013721 (1985).","journal-title":"Arch. Pathol. Lab Med."},{"key":"2922_CR52","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/sj.bjc.6602184","volume":"91","author":"D Abd El-Rehim","year":"2004","unstructured":"Abd El-Rehim, D. et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer 91, 1532\u20131542 (2004).","journal-title":"Br. J. Cancer"},{"key":"2922_CR53","doi-asserted-by":"publisher","DOI":"10.7717\/peerj-cs.67","volume":"2","author":"J Anaya","year":"2016","unstructured":"Anaya, J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput. Sci. 2, e67 (2016).","journal-title":"PeerJ Comput. Sci."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02922-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02922-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02922-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:28:05Z","timestamp":1790245685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02922-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02922-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"411"}}